Strumento inattivo

Altre lingue Ampliphi Biosciences Corp Nyse

Azioni

APHB

US03211P2020

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection	12/07
Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024	11/07
Armata Pharmaceuticals, Inc. Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled Ap-Pa02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas Aeruginosa Infection	11/07
Armata Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05
Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q1 Revenue $966,000	07/05
Armata Pharmaceuticals : Shareholder Meeting - Form 8-K	22/03
Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q4 Revenue $1.5M	21/03
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	21/03
Armata Pharmaceuticals Secures $35 Million Credit Agreement From Innoviva Unit	04/03
Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update	15/11
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference	30/10/23
Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus	27/09/23
Armata Pharmaceuticals, Inc. Announces First Patient Dosed in the Phase 2A Portion of the Phase 1b/2a 'Disarm' Study of Ap-Sa02 in Adults with Bacteremia Due to Staphylococcus Aureus	26/09/23
Armata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference	22/09/23
Armata Pharmaceuticals, Inc. Announces CFO Changes	20/09/23
Armata Pharmaceuticals, Inc. Announces Executive Changes	20/09/23
Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update	15/08/23
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Ampliphi Biosciences Corp Nyse

Azioni

APHB

US03211P2020

Altre lingue

Filtri